Teva Pharmaceutical Industries Ltd. (
) recently announced that it has gained US Food and Drug
Administration (FDA) approval for its generic version of
) Adderall XR capsules (5mg, 10mg, 15mg, 20mg, 25mg and 30
According to IMS, Adderall XR, which is approved for the
treatment of attention deficit hyperactivity disorder, delivered
annual sales (both branded and generic) of about $2 billion in
the US as of Dec 31, 2012.
Teva already sells a generic version of Adderall XR under a 2006
license and distribution agreement with Shire. Per the terms of
the agreement, Shire has to supply product to Teva through Apr 1,
With the FDA granting final approval, Teva can now remain in the
Adderall XR market even after the expiry of its supply agreement
Teva currently carries a Zacks Rank #3 (Hold). The company, which
is going through a transition period, provided disappointing
guidance for 2013. However, with the company not including the
impact of its cost-savings plan in its guidance, we believe Teva
is leaving some room for delivering above expectations. Share
buybacks also leave some room for upside.
We expect investor focus to remain on the execution of the
company's new strategy. Earlier this year, Teva sold off its
animal health business in the US to
). This will allow the company to focus on developing,
manufacturing and marketing branded and generic drugs globally --
Teva's primary areas of strength.
Among generic companies,
) currently looks better-positioned with a Zacks Rank #2 (Buy).
Shire also carries a Zacks Rank #2.
BAYER A G -ADR (BAYRY): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.